US Patent

US10058504 — Methods for the preparation of injectable depot compositions

Formulation · Assigned to Laboratorios Farmaceuticos Rovi SA · Expires 2031-05-31 · 5y remaining

Vulnerability score 44/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects methods for preparing injectable depot compositions that can release therapeutic levels of a drug, such as Risperdal, for at least 14 days.

USPTO Abstract

Injectable depot compositions, comprising a biocompatible polymer which is a polymer or copolymer based on lactic acid and/or lactic acid plus glycolic acid having a monomer ratio of lactic to glycolic acid in the range from 48:52 to 100:0, a water-miscible solvent having a dipole moment of about 3.7-4.5 D and a dielectric constant of between 30 and 50, and a drug, were found suitable for forming in-situ biodegradable implants which can evoke therapeutic drug plasma levels from the first day and for at least 14 days.

Drugs covered by this patent

Patent Metadata

Patent number
US10058504
Jurisdiction
US
Classification
Formulation
Expires
2031-05-31
Drug substance claim
No
Drug product claim
Yes
Assignee
Laboratorios Farmaceuticos Rovi SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.